Samsung C&T Says Samsung Biologics Delays PolyPeptide Acquisition to Dec. 31, 2026
Samsung C&T corrected Samsung Biologics' planned PolyPeptide acquisition settlement date to Dec. 31, 2026, from Nov. 30, 2026. The planned cash acquisition covers 33,016,411 shares for KRW 2.71 trillion, aimed at strengthening its peptide CDMO business. Disclaimer: This news brief was created by Public Technologies (PU